GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Shares Buyback Ratio %

Karolinska Development AB (Karolinska Development AB) Shares Buyback Ratio % : 0.00 (As of May. 20, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Karolinska Development AB's current shares buyback ratio was 0.00%.

Karolinska Development AB Shares Buyback Ratio % Historical Data

The historical data trend for Karolinska Development AB's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Shares Buyback Ratio % Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -173.35 - - -36.21 -

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Karolinska Development AB Shares Buyback Ratio % Calculation

Karolinska Development AB's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2022 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Dec. 2022 )
=(269.833 - 269.833) / 269.833
=0.00%

Karolinska Development AB's Shares Buyback Ratio for the quarter that ended in Mar. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2023 ) - Shares Outstanding (EOP) (A: Mar. 2024 )) / Shares Outstanding (EOP) (A: Dec. 2023 )
=(269.833 - 269.833) / 269.833
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karolinska Development AB Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Karolinska Development AB (Karolinska Development AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Shares Buyback Ratio %
Comparable Companies
OSTO:MVIR OSTO:NICA OSTO:INDEX OSTO:IVACC OSTO:IRLAB A OSTO:IMMU OSTO:SANION OSTO:GUARD OSTO:INIT OSTO:KAN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KDEV:Sweden 2I9:Germany
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Website
https://www.karolinskadevelopment.com
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.